Microdosing Ozempic? The GLP-1 Comeback You Didn’t See Coming
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Microdosing Ozempic? The GLP-1 Comeback You Didn’t See Coming
-
Lu par :
-
De :
À propos de ce contenu audio
The boys are back—new (temporary) studio, same no-BS approach.
Dr. Ken Brown and Eric Rieger dive deep into the unexpected resurgence of GLP-1 medications like Ozempic and Wegovy—this time, with a controversial twist: microdosing. Is less actually more? Can tiny doses of these peptides do more than just shed pounds? Think anxiety relief, autoimmune improvement, and possibly ditching antidepressants altogether. 🤯
In this episode, you’ll learn:
- Why the original weight-loss hype may have missed the mark
- The shocking mental health benefits patients are reporting
- How the gut-brain axis could be the key to mood, metabolism & more
- The dark side of big doses: muscle loss, acid reflux, thyroid risks, and sky-high costs
- Why doctors are thinking outside the FDA box—and what it could mean for you
Whether you’ve tried these meds, are skeptical, or are just here for the banter, this episode blends science, sarcasm, and some serious truth bombs.
🎧 Tap play. This one’s for anyone who’s tired of one-size-fits-all medicine and wants to explore the future of gut-driven wellness.
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
Aucun commentaire pour le moment